[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subarachnoid-aneurysm-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subarachnoid-aneurysm-hemorrhage":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,73,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640976","early-motor-cognitive-integrative-training-on-cognitive-and-motor-performance-in-patients-with-aneurysmal-subarachnoid-hemorrhage-100640976",false,"NCT07588997","Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage","The Efficacy of Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* (1) Diagnosis of spontaneous SAH resulting from aneurysm rupture confirmed by either CT scan or angiography. (2) Onset of stroke occurring in the acute phase, specifically 2-7 days after medical intervention. (3) Participants must be over 18 years old. (4) WFNS: 1-5. (5) Able to stand above 30 seconds. (6) Montreal Cognitive Assessment (MoCA)\\\u003C26.\n\nExclusion Criteria:\n\n* (1)unstable vital sign. (2)patients evaluated as unsuitable by their attending physician. (3)those with other neurological diseases that might interfere with the experiment. (4)less than 12 years of education will be excluded from this study.","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"NA","Despite its lower incidence rate within the stroke population and tendency to affect younger individuals, SAH carries the highest risk of PSCI. The neural mechanisms underlying these cognitive deficits remain poorly understood, but potential factors include treatment approaches, underlying disease pathophysiology, post-disease complications, or alterations in neural connectivity\\[10\\]. Previous literature indicates that cognitive deficits in SAH primarily manifest in areas such as visuospatial skill, verbal memory language abilities (including verbal comprehension, verbal fluency, abstract language), executive function (working memory) and attention. These impairments significantly impact patients' ability to perform ADL independently and return to work, despite motor function recovery.",[26],"Subarachnoid Aneurysm Hemorrhage",[28,29,30],"Spontaneous subarachnoid hemorrhage","post-stroke cognitive impairment","motor-cognitive integrative training","RECRUITING","2026-05-08",{"date":34,"type":35},"2026-05-15","ACTUAL",{"date":37,"type":35},"2025-11-23",{"date":39,"type":20},"2027-12",{"name":41,"class":42},"National Taiwan University Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100626771","investigation-of-protein-heterogeneity-in-extracellular-vesicles-derived-from-different-human-blood-circulatory-regions-100626771","NCT07439965","Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions","DBCR-EV-p","Inclusion Criteria:\n\n* 1\\. Aged between 18 and 60 years, regardless of gender; 2. Diagnosed with intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have CT imaging evidence of hemorrhage, and blood collection must occur within 3 days of symptom onset; 4. Scheduled to undergo neurointerventional surgery for intracranial aneurysm under general anesthesia, with the procedure starting between 8:00 AM and 12:00 PM; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with a pre-onset (in hemorrhagic cases) or preoperative (in non-hemorrhagic cases) Modified Rankin Scale (MRS) score ≥ 2; 2. Presence of other neurological disorders such as Parkinson's disease, Alzheimer's disease, cerebral infarction, brain tumors, epilepsy, etc.; 3. Presence of other systemic diseases such as diabetes, coronary artery disease, cancer, infections, hematological diseases, or severe metabolic disorders that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT \\> 3 times the upper limit of normal; creatinine \\> 225 μmol\u002FL); 5. Patients who cannot tolerate anesthesia, anticoagulant therapy, or who have coagulation disorders; 6. History of severe allergic reactions to contrast agents; 7. Pregnant women; 8. Patients participating in other clinical trials who have not yet completed follow-up.","60 Years",{"count":53,"type":20},120,"120 Days","OBSERVATIONAL","The goal of this observational study is to learn about the protein heterogeneity in extracellular vesicles (EVs) derived from different human blood circulatory regions of patients with ruptured or unruptured intracranial aneurysms. The main objectives are:\n\nReveal the proteomic heterogeneity of EVs in different blood circulatory regions of the human body。 Reveal the proteomic differences of EVs in cerebral feeding arteries and draining veins between patients with aneurysmal subarachnoid hemorrhage and those without hemorrhage.\n\nExplore EV-derived protein biomarkers that reflect the diagnosis and prognosis of subarachnoid hemorrhage",[26,58],"Unruptured Intracranial Aneurysm",[60,61,62,63],"extracellular vesicles","blood","subarachnoid hemorrhage","intracranial aneurysm","2026-02-23",{"date":66,"type":35},"2026-02-27",{"date":68,"type":35},"2025-07-29",{"date":70,"type":20},"2026-06",{"name":72,"class":42},"The First Hospital of Jilin University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100598008","nimodipine-variability-in-sah-100598008","NCT07065903","Nimodipine Variability in SAH","Nimodipine Systemic Exposure and Outcomes Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Multi-centre Observational Study (ASH-II Study)","ASH-II","Inclusion Criteria:\n\n* Age 18-85 years\n* Diagnosis of aneurysmal SAH\n* Provision of informed consent\n* Treated with nimodipine\n* Presence of intravascular catheter at the time of sampling\n\nExclusion Criteria:\n\n* Anticipated hospital length of stay \\\u003C48 hours\n* Non-aneurysmal SAH\n* Not treated with nimodipine\n* Incarceration\n* Delayed presentation to the hospital (\\>96 h from SAH onset)","85 Years",{"count":83,"type":20},500,"Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patients during their most productive years. Complications following SAH are common, and they can cause major long-term disability. Only one medication - nimodipine - has been proven to benefit the health and wellbeing of these patients. All SAH patients should receive nimodipine for 21 days at a fixed dose. However, our early work suggested that all patients are not getting equal amounts of nimodipine into their blood. In addition, the two different forms (structural mirror images) of nimodipine might have different effects. Reduced amounts of nimodipine in the blood may lessen its benefit and contribute to worsening health and wellbeing of SAH patients.\n\nThe overall goal of this research is to see what happens with different nimodipine doses and to confirm whether the two forms of nimodipine have different effects. The investigators will conduct a multi-centre study in adult patients admitted for SAH in Canada and the USA. The investigators will collect blood samples to determine the amount of each type of nimodipine in each participant's body, and then will check to see how each participant is doing at 90 days following SAH. They will also check other factors affecting nimodipine levels, so that they can in the future suggest dose recommendations that are actually tailored to each patient.",[26,86],"Subarachnoid Hemorrhage, Aneurysmal",[88,62,89],"nimodipine","pharmacokinetics","2026-02-04",{"date":92,"type":35},"2026-02-09",{"date":94,"type":35},"2024-05-13",{"date":96,"type":20},"2029-09",{"name":98,"class":42},"University of Alberta",3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100616462","delayed-cerebral-infarction-beyond-endoluminal-spasmolysis-and-induced-hypertension-100616462","NCT07305922","Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension","Decibel","Inclusion Criteria:\n\n* Adults 18 years or older\n* Critical care after subarachnoid haemorrhage\n* Aneurysm secured by surgical clipping or endovascular procedure\n* Suspected, emerging or established severe cerebral vasospasm\n\nExclusion Criteria:\n\n* Anticipated survival less than five days, as determined by treating clinician\n* Transcranial Doppler signal too weak\n* Pregnancy",{"count":108,"type":20},200,"An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.",[26,111],"Cerebral Vasospasm After Subarachnoid Hemorrhage",[113,114,115,116],"Transcranial Doppler","Endoluminal Spasmolysis","Induced Hypertension","Multimodal Neuromonitoring","2025-12-18",{"date":119,"type":35},"2025-12-26",{"date":121,"type":35},"2025-12-01",{"date":123,"type":20},"2030-12-31",{"name":125,"class":126},"Region Stockholm","OTHER_GOV"]